



HAL
open science

The genetic basis of congenital hyperinsulinism

Chela James, Ritika K Kapoor, Dunia Ismail, Khalid Hussain

► **To cite this version:**

Chela James, Ritika K Kapoor, Dunia Ismail, Khalid Hussain. The genetic basis of congenital hyperinsulinism. *Journal of Medical Genetics*, 2009, 46 (5), pp.289. 10.1136/jmg.2008.064337. hal-00552677

HAL Id: hal-00552677

<https://hal.science/hal-00552677>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The genetic basis of congenital hyperinsulinism

Chela James, Ritika R Kapoor, Dunia Ismail, Khalid Hussain

London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, and The Institute of Child Health, University College London WC1N 1EH UK.

Correspondence to Dr. K. Hussain
Developmental Endocrinology Research Group
Clinical and Molecular Genetics Unit
Institute of Child Health
University College London
30 Guilford Street, London WC1N 1EH.
Tele: ++44 (0)20 7 905 2128
Fax: ++44 (0)20 7 404 6191
Email K.Hussain@ich.ucl.ac.uk

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Journal of Medical Genetics and any other BMJ PGL products to exploit all subsidiary rights, as set out in our licence (<http://jmg.bmj.com/iforalicence.pdf>).

Abstract

Congenital hyperinsulinism (CHI) is biochemically characterised by the dysregulated secretion of insulin from pancreatic β -cells. It is a major cause of persistent hyperinsulinaemic hypoglycaemia (HH) in the **newborn** and infancy period. Genetically CHI is a heterogeneous condition with mutations in seven different genes described. The genetic basis of CHI involves defects in key genes which regulate insulin secretion from β -cells. Recessive inactivating mutations in *ABCC8* and *KCNJ11* (which encode the two subunits of the adenosine triphosphate-sensitive potassium channels, ATP sensitive K_{ATP} channels) in β -cells are the most common cause of CHI. The other recessive form of CHI is due to mutations in *HADH* (encoding for 3-hydroxyacyl-Coenzyme A dehydrogenase). Dominant forms of CHI are due to inactivating mutations in *ABCC8* and *KCNJ11*, and activating mutations in *GLUD1* (encoding glutamate dehydrogenase) and, *GCK* (encoding glucokinase). Recently dominant mutations in *HNF4A* (encoding Hepatocyte nuclear factor 4 alpha) and *SLC16A1* (encoding monocarboxylate transporter 1) have been described which lead to HH. Mutations in all these genes account for about 50% of the known causes of CHI. Histologically there are **three (possibly others which have not been characterised yet)** major subtypes of CHI, diffuse, focal **and atypical forms**. The diffuse form is inherited in an autosomal recessive (or dominant manner) and the focal form being sporadic in inheritance. The diffuse form of the disease may require a near total pancreatectomy whereas the focal form requires a limited pancreatectomy potentially curing the patient. Understanding the genetic basis of CHI has not only provided novel insights into β -cell physiology but also aided in patient management and genetic counseling.

Introduction

Congenital hyperinsulinism (CHI) is biochemically characterised by the dysregulated secretion of insulin from pancreatic β -cells. It is a major cause of hypoglycaemia in the newborn and infancy period.[1] The unregulated insulin secretion drives glucose into insulin sensitive tissues (skeletal muscle, liver and adipose tissue) and prevents the generation of alternative energy substrates (such as ketone bodies) thus depriving the brain of both its primary and secondary energy sources. [2] This prevailing metabolic milieu is the main factor leading to hypoglycaemic brain injury and mental retardation in this group of patients.

The incidence of CHI can vary from 1 in 40,000-50,000 in the general population to 1 in 2,500 in some isolated communities with high rates of consanguinity.[3-5] It is a heterogeneous condition with regards to the clinical presentation, the underlying genetic aetiology, molecular mechanisms and histological basis of the disease.[6-9] The clinical presentation can be heterogeneous ranging from completely asymptomatic, mild medically responsive to severe medically unresponsive disease which may require a near total pancreatectomy. Those patients undergoing a total pancreatectomy have a high risk of developing post pancreatectomy diabetes mellitus and pancreatic exocrine insufficiency

Insulin secretion from β -cells is precisely regulated to maintain blood glucose levels within the normal range (3.5-5.5mmol/L). The genetic basis of CHI involves defects in key genes which regulate insulin secretion from β -cells. The most common cause of CHI are recessive inactivating mutations in *ABCC8* and *KCNJ11* which encode the two subunits of the adenosine triphosphate-sensitive potassium channels (ATP sensitive K_{ATP} channels) in the pancreatic β -cell.[10-17] These β -cell K_{ATP} channels play a key role

in transducing signals derived from glucose metabolism to β -cell membrane depolarization and regulated insulin secretion.[18] The other rare recessive form of CHI is due to mutations in *HADH* (encoding for-3-hydroxyacyl-Coenzyme A dehydrogenase).[19-21] Dominant forms of CHI are due to inactivating mutations in *ABCC8* and *KCNJ11*,[22-25] and activating mutations in *GLUD1* (encoding glutamate dehydrogenase),[26-31] *GCK* (encoding glucokinase), [32-38] *HNF4A* (encoding Hepatocyte nuclear factor 4 alpha) [39-41] and *SLC16A1* (encoding monocarboxylate transporter 1).[42] Mutations in all these genes account for about 50% of the known causes of CHI, and in some populations mutations in these genes account for only about 20% of CHI cases [5, 9, 43, 44] suggesting other novel genetic aetiologies.

Histologically there are three major subgroups of the disease namely diffuse, focal and atypical.[45, 46] The diffuse forms of CHI are inherited in an autosomal recessive or dominant manner and the focal form is sporadic in inheritance. The diffuse form of the disease may require a near total pancreatectomy (with a high risk of developing diabetes mellitus) whereas the focal form requires a limited pancreatectomy offering a complete “cure” for the patient. **In atypical patients lesions are either more extensive while remaining limited, or diffuse with the coexistence of normal and abnormal islets.**[46]

Understanding the genetic basis of CHI has not only provided novel insights into β -cell physiology but also aided in patient management and genetic counseling. In terms of patient management rapid genetic analysis for mutations in *ABCC8* and *KCNJ11* can help in the genetic diagnosis of diffuse or focal CHI.[47] Prenatal diagnosis of CHI based on the genetic analysis of known family members with mutations in *ABCC8* (and *KCNJ11*) is also now possible permitting immediate medical management at the time of birth.[48] This state of the art review will firstly give a brief overview of the role of β -cell

K_{ATP} channels in regulating insulin secretion and then focus in detail on the genetic and molecular basis of CHI due to mutations in the known genes and highlight some of the more recent genetic advances. Table 1 summarises the known genetic causes of CHI.

The role of K_{ATP} channels in regulating glucose induced insulin secretion

K_{ATP} channels have a key role in the physiology of many cells, and defects either in the channel itself or in its regulation can lead to diseases in humans.[49, 50] Functionally K_{ATP} channels provide a means of linking the electrical activity of a cell to its metabolic state by sensing changes in the concentration of intracellular nucleotides and in some cases they mediate the actions of hormones and transmitters.[51] **The pancreatic K_{ATP} channel is a functional complex of the sulfonylurea receptor 1 (SUR1) and an inward rectifier potassium channel subunit (Kir6.2) and plays a pivotal role in regulating insulin secretion from the β-cell.[52] The Kir6.2 forms the pore of the channel and the SUR1 (an ATP Binding Cassette Transporter) acts as a regulatory subunit.**

K_{ATP} channels are regulated by adenine nucleotides to convert changes in cellular metabolic levels into membrane excitability. Each subunit of the K_{ATP} channel is known to be differentially regulated. The Kir6.2 subunit determines the biophysical properties of the channel complex including K⁺ selectivity, rectification, inhibition by ATP and activation by acyl-CoAs.[53] The sulfonylurea receptors endow K_{ATP} channels with sensitivity to the stimulatory actions of Mg-nucleotides and K_{ATP} channel openers (e.g. diazoxide, nicorandil) and the inhibitory effects of sulphonylureas and glinides[54] **and endosulfins.[55]**

The molecular topology of SUR1 consists of three transmembrane domains TMD0, TMD1, and TMD2, each of which consists of five, five, and six membrane spanning regions, respectively.[56] SUR1 also has two nucleotide binding folds (NBF-1 and NBF-2) on the cytoplasmic side with which it senses changes in intracellular [ATP]/[ADP] and transmits the signal to the pore. NBF1 appears to be the principal site for ATP binding, whereas NBF2 binds MgADP.[56] NBF-1 and NBF-2 are located in the loop between TMD1 and TMD2 and in the C-terminus, respectively. These binding domains cooperate with each other in mediating the nucleotide regulation of the pore function.[57] NBFs of SUR contain highly conserved motifs among ABC proteins: Walker A motif, Walker B motif, ABC signature motif (also called linker sequence or LSGGQ motif), and an invariant glutamine and histidine residue (also called the Q-loop and H-loop, respectively). Walker A and Walker B motifs are directly involved in nucleotide binding.[58]

K_{ATP} channels can only function if they are assembled and correctly transported to the cell membrane surface (trafficking). The assembly and trafficking of K_{ATP} channels are intricately linked processes. Only octameric K_{ATP} channel complexes are capable of expressing on the cell membrane surface. For example both Kir6.2 and SUR1 possess an endoplasmic reticulum (ER) retention signal (RKR) that prevents the trafficking of each subunit to the plasma membrane in the absence of the other subunit.[59] **Correct assembly** of the two subunits masks these retention signals, allowing them to traffic to the plasma membrane. The retention signal is present in the C terminal region of Kir6.2 and in an intracellular loop between TM11 and NBF-1 in SUR1. Truncation of the C-terminus of Kir6.2 deletes its retention signal, allowing functional expression of Kir6.2 in the absence of SUR1 subunit.[60] In addition to these retrograde signals, the C terminus of SUR1 has an anterograde signal, composed in part of a dileucine motif and

downstream phenylalanine, which is required for K_{ATP} channels to exit the ER/cis-Golgi compartments and transit to the cell surface.[61] Deletion of as few as seven amino acids, including the phenylalanine, from SUR1 markedly reduces surface expression of K_{ATP} channels.[62] Thus, one function of SUR is as a chaperone protein, to facilitate the surface expression of Kir6.2. There is also some evidence that Kir6.2 provides a reciprocal service for SUR.[63]

The SUR1 protein shows a high-affinity binding capacity to the sulfonylurea glibenclamide, indicating that SUR1 confers sulfonylurea binding.[64, 65] The sulfonylurea drugs (glibenclamide and tolbutamide) inhibit the channels and are used in the treatment of non-insulin-dependent (type II) diabetes mellitus. The other class of drugs, known as potassium channel openers (*e.g.* diazoxide), activate the channel and are used to suppress insulin secretion. [65]

Genetic basis of CHI due to recessive inactivating mutations in *ABCC8* and *KCNJ11*

The *ABCC8* gene consists of 39 exons and spans more than 100kb of genomic DNA.[66] The human SUR1 cDNA contains a single open reading frame that encodes for 1,582 amino acids with a molecular weight of 177kDa (GenBank NM_000352.2). Kir6.2 consists of a single exon encoding for a protein of 390 amino acids (GenBank NM_000525.2).[52] The *ABCC8* and *KCNJ11* genes are both located on chromosome 11p15.1, separated by only a small stretch of 4.5 kb of DNA.[66] Homozygous, compound heterozygous and heterozygous recessive inactivating mutations (missense, frameshift, nonsense, insertions/deletions (macrodeletion), splice site and regulatory mutations) have been reported in *ABCC8* and *KCNJ11*. [10-17, 67, 68] So far more than

150 mutations have been reported in *ABCC8* and 25 in *KCNJ11*. [69] In the Ashkenazi Jewish population two common mutations (F1388del and c.3992–9G4A) account for 90% of all cases of CHI [9,10] whereas in the Finnish population, two founder mutations have been reported (V187D and E1507 K). [14, 22] Recessive inactivating mutations in *ABCC8* and *KCNJ11* usually cause severe CHI which in the vast majority of patients is unresponsive to medical therapy with diazoxide. However some compound heterozygote mutations may be milder and may respond to treatment with diazoxide. [70] Compound heterozygote mutations may result in complex interactions resulting in intracellular retention of channel complexes. [71] The molecular basis of recessive inactivating *ABCC8* and *KCNJ11* mutations involves multiple defects in K_{ATP} channel biogenesis and turnover, in channel trafficking from the endoplasmic reticulum and Golgi apparatus to the plasma membrane and alterations of channels in response to both nucleotide regulation and open-state frequency. Figure 1 shows a schematic outline of the β -cell K_{ATP} channel and locations of the some of the common mutations.

Recessive ABCC8 and KCNJ11 mutations resulting in defects in channel biogenesis and turnover

The mechanisms that control the maturation and assembly of K_{ATP} channels are not well understood. Pulse-labeling studies have shown that when Kir6.2 is expressed individually, its turnover is biphasic with about 60% being lost with a half life of 36 min. [72] The remainder converts to a long-lived species (half life 26 h) with an estimated halftime of 1.2 h. Expressed alone SUR1 has a long half-life of 25.5 h. When Kir6.2 and SUR1 are co-expressed, they associate rapidly and the fast degradation of Kir6.2 is eliminated. [72] Two mutations, *KCNJ11* (W91R) and *ABCC8* (F1388del), identified in patients with the severe form of CHI, profoundly alter the rate of Kir6.2 and SUR1 turnover, respectively. [72] Both mutant subunits associate with their respective partners

but dissociate freely and degrade rapidly suggesting that the mutations alter channel biogenesis and turnover.

Recessive inactivating mutations in ABCC8 and KCNJ11 resulting in defects in channel trafficking

Trafficking of K_{ATP} channels requires that the endoplasmic reticulum-retention signal, RKR, present in both SUR1 and Kir6.2 is shielded during channel assembly. Some mutations in *ABCC8* (such as R1437Q(23)X, F1388del and R1394H0) cause a trafficking defect by affecting the exit of channel subunits from the endoplasmic reticulum compartment.[13, 73, 74, 75] The R1437Q(23)X, mutation in exon 35 of *ABCC8* truncates 200 amino acids from the COOH-terminal region of the protein, an area that contains the anterograde signaling sequence (L1566, L1567.F1574) and residue L1544 which is part of the cloaking region for the RKR sequence.[76] This defect affects the exit of channel subunits from the endoplasmic reticulum.

The pivotal role played by the RKR signal in allowing the channels to express correctly on the β -cell membrane is illustrated by the fact that when the RKR signal is inactivated by an in-frame deletion (F1388del SUR1_{AAA}), channel activity is impaired, but when surface expression is rescued, the channels function normally.[73] Other mutations such as the R1394H (*ABCC8*) cause a trafficking disorder by effecting retention of mutant proteins in the *trans*-Golgi network.[74]

Mutations in *KCNJ11* can also cause defective trafficking and truncated non functional proteins. For example the Kir6.2 mutation (Y12X) causes the synthesis of a truncated nonfunctional protein [12] whereas another mutation (W91R) leads to defective channel assembly with a rapid degradation in the endoplasmic reticulum (ER).[72] Recently a

new homozygous mutation H259R (*KCNJ11*) has been shown to lead to a nonfunctional K_{ATP} channels with impaired trafficking to the cell membrane.[16]

Recessive inactivating mutations in ABCC8 and KCNJ11 resulting in defects of channel regulation

The SUR1 subunit plays a key role in determining the pharmacological regulation of K_{ATP} channels with SUR1 acting as a conductance regulator of Kir6.2. The sensitivity of K_{ATP} channels to changes in ATP, ADP, and guanosine (GTP, GDP) nucleotides involves both subunits. The functional regulation of K_{ATP} channels is induced by changes in the ATP/ADP ratio. This involves cooperative interactions of nucleotides at both subunits with the actions of ATP-induced inhibition of Kir6.2 being countered by the activation of ADP at SUR1. Hence mutations that affect the regulation of the K_{ATP} channels by altering its sensitivity to changes in ADP/ATP will lead to unregulated insulin secretion. Several mutations in *ABCC8* (for example R1420C, T1139M and R1215Q) have now been described that result in the loss of ADP-dependent gating properties of the channel.[75, 77, 78]. Loss of ADP-dependent gating results in the constitutive inhibition of K_{ATP} channels by ATP.

Dominant inactivating *ABCC8* and *KCNJ11* mutations causing CHI

Dominant inactivating mutations in *ABCC8* and *KCNJ11* have been described which lead to CHI.[22-25] However the phenotype of patients with dominant inactivating mutations in *ABCC8* and *KCNJ11* seems to be much milder than that of patients with recessive inactivating *ABCC8* and *KCNJ11* mutations. Patients with dominant mutations seem to be responsive to medical therapy with diazoxide, may present later than those with recessive mutations and do not require a pancreatectomy.[24] In one large study of

16 families with dominant CHI caused by mutations in *ABCC8* or *KCNJ11* all of the mutations were conservative single–amino acid changes, allowing for normal channel formation at the plasma membrane.[24] Whereas recessive mutations cause near absence of K_{ATP} channel activity (to have defects in channel biogenesis or trafficking of mature functional channels to the plasma membrane) dominant mutations demonstrate normal channel assembly with their respective wild type partner and normal trafficking of assembled channels to the plasma membrane when expressed in vitro.

A dominant missense CHI causing mutation F55L (*KCNJ11*) has been shown to greatly reduce the open probability of K_{ATP} channels in intact cells without affecting channel expression.[25] It was shown that the low channel activity was due to reduced channel response to membrane phosphoinositides and/or long-chain acyl-CoAs, as application of exogenous PIP_2 or oleoyl-CoA restored channel activity similar to that seen in wild type channels. These electrophysiological observations provide a link between K_{ATP} channels and their regulation by membrane phosphoinositides and/or long-chain acyl-CoAs.[79]

Dominant activating mutations in *GLUD1*

The *GLUD1* gene is located on chromosome 10q23.3 and contains 13 exons coding for a 505-amino acid mature enzyme (Glutamate dehydrogenase GDH).[80] GDH is a mitochondrial matrix enzyme which is expressed at high levels in the liver, brain, kidney, pancreas, heart and lungs.[81] This enzyme catalyzes the oxidative deamination of glutamate to α -ketoglutarate and ammonia using NAD^+ and/or $NADP^+$ as co-factors. In the β -cell α -ketoglutarate enters the TCA cycle and leads to an increase in the cellular ATP. This increases the ATP/ADP ratio which triggers closure of the K_{ATP} channels and depolarisation of the β -cell membrane. This, in turn opens the voltage gated calcium channel, raises the cytosolic calcium, and triggers the release of insulin. GDH plays a

critical step in glutaminolysis and regulating amino acid induced insulin secretion.[82] Its activity is regulated by a complex interplay of allosteric activators and inhibitors. Positive allosteric effectors of GDH include leucine, and ADP (adenine diphosphate), whereas GTP (guanosine 5"-triphosphate) is a potent allosteric inhibitor.[83] Allosteric activation of glutaminolysis is one mechanism by which the amino acid leucine stimulates insulin secretion.[83]

Activating mutations (heterozygous missense single amino acid substitutions) in the *GLUD1* gene are the second commonest cause of CHI. *GLUD1* gene mutations cause a form of CHI in which affected children have recurrent symptomatic HH together with a persistently elevated plasma ammonia level, the Hyperinsulinism/ Hyperammonaemia (HI/HA) syndrome.[26, 84-86] The mutations causing HI/HA reduce the sensitivity of the enzyme to allosteric inhibition by the high-energy phosphate GTP [27,86] and in rare cases increase basal GDH activity.[28, 29, 87] The loss of inhibition by GTP increases the rate of oxidation of glutamate in the presence of leucine, thereby increasing insulin secretion. The clinical picture is hence characterized by postprandial hypoglycaemia following a protein meal (fasting hypoglycaemia may also occur). The mechanism of persistent hyperammonaemia, [86, 88] a striking and consistent feature of this condition, is not completely understood. **The hypoglycaemia in patients with HI/HA syndrome is usually responsive to medical therapy with diazoxide. The hyperammonaemia is considered to be asymptomatic and hence efforts to reduce plasma ammonia levels with sodium benzoate or *N*-carbamyglutamate do not seem to be beneficial.**

Glutamate dehydrogenase is a homohexameric enzyme with two trimeric subunits; each subunit is composed of at least three domains. Mutations in *GLUD1* occur most commonly in the GTP allosteric binding domain of GDH (exons 11 and 12).[26, 27]

Mutations in the catalytic domain (exons 6 and 7) have also been identified.[29, 30] This domain interacts with GTP molecules and mutations in the allosteric and catalytic domains have been shown to cause hyperinsulinism by diminishing the sensitivity of GDH to GTP. The third domain is an antenna-like structure connecting to the pivot helix where mutations (exon 10) have also been reported.[28, 31] Functional analysis of these mutations has shown that they are associated with a higher basal GDH activity and a milder insensitivity to GTP inhibition in comparison with mutations in the other two domains.[28, 31] Most cases of HI/HA syndrome occur sporadically however families with HI/HA syndrome where the mutation has been dominantly inherited have also been described.[30] Figure 2 summarises the mutations in the *GLUD1* gene known to cause CHI.

Dominant activating mutations in *GCK*

The glucokinase gene (*GCK*) is located on chromosome 7p15.3-p15.1 and comprises of 12 exons which span ~45,168bp and encode for a 465 amino acid protein with a molecular weight of 52,191Da. The gene is transcribed in various tissues but it has tissue specific promoters and is especially expressed in the pancreas, liver, and brain.[89] The presence of tissue-specific promoters allows differential regulation and transcription of different transcripts giving rise to three different-sized versions of exon 1 (a, b, and c). In the pancreas the upstream promoter is functional, while in the liver the downstream promoter is used. Exon 1a is expressed in the pancreatic β -cells whereas exons 1b and 1c are expressed in the liver.[89]

Glucokinase (hexokinase IV or D) is one member of the hexokinase family of enzymes. The name, glucokinase, is derived from its relative specificity for glucose under

physiologic conditions. Glucokinase is a key regulatory enzyme in the pancreatic β -cells. It operates as a monomer and phosphorylates glucose on carbon 6 with MgATP as a second substrate to form glucose-6-phosphate (G6P) as a first step in the glycolytic pathway. It plays a crucial role in the regulation of insulin secretion and has been termed the pancreatic β -cell sensor on account of its **kinetics because the rate of phosphorylation of glucose in the pancreatic β -cells is directly related to the concentration of glucose over a range of physiological glucose concentrations (4–15mmol/l).**[90] These kinetic characteristics are the enzyme's low affinity for glucose (concentration of glucose at which the enzyme is half maximally activated, $S_{0.5}$, 8–10mmol/l), cooperativeness with glucose (Hill number of ~ 1.7), and lack of inhibition by its product G6P.[90] The enzyme has at least two clefts, one for the active site, binding glucose and MgATP and the other for a putative allosteric activator. Glucokinase activity is closely linked to the K_{ATP} and calcium channels of the β -cell membrane, resulting in a threshold for glucose-stimulated insulin release of approximately 5mmol/L, which is the set point of glucose homeostasis.[91]

Heterozygous inactivating mutations in *GCK* cause maturity-onset diabetes of the young (MODY), homozygous inactivating in *GCK* mutations result in permanent neonatal diabetes whereas heterozygous activating *GCK* mutations cause CHI. So far seven activating *GCK* mutations (V455M, A456V, Y214C, T65I, W99R, G68V, S64Y) have been described that lead to CHI (Figure 3).[32-38] Activating *GCK* mutations increase the affinity of *GCK* for glucose and alter (reset) the threshold for glucose stimulated insulin secretion. All reported activating mutations cluster in a region of the enzyme, which has been termed the allosteric activator site and is remote to the substrate-binding site. The allosteric site of *GCK* is where small molecule activators bind, suggesting a critical role of the allosteric site in the regulation of *GCK* activity.[92]

Both GCK activators and activating mutations increase enzyme activity by enhancing the affinity for glucose as described by a decrease in $K_{0.5}$.^[93] There is no evidence to suggest that over-expression of GCK (increased gene dosage effect) is a likely cause of CHI.^[94]

The clinical symptoms and course of patients with GCK mutations cover a broad spectrum from asymptomatic hypoglycaemia to unconsciousness and seizures, even within the same family with the same mutation, implicating a complex mechanism for GCK regulation. Patients with activating GCK mutations may present with postprandial hyperinsulinaemic hypoglycaemia.^[95] Most of the GCK mutations reported to date cause mild diazoxide responsive CHI. However a “de novo” mutation in GCK (Y214C) was described in a patient with medically unresponsive CHI.^[35] This mutation was located in the putative allosteric activator domain of the protein and functional studies of purified recombinant glutathionyl S transferase fusion protein of GK-Y214C showed a sixfold increase in its affinity for glucose, a lowered cooperativity, and increased k_{cat} .^[35] The relative activity index of GKY214C was 130, and the threshold for glucose stimulated insulin secretion was predicted by mathematical modelling to be 0.8mmol/l, as compared with 5mmol/l in the wild-type enzyme.^[35] In the largest study performed to date on a pool of patients who were negative for mutations in the *ABCC8* and *KCNJ11* genes the prevalence of CHI due to mutations in GCK was estimated to be about 7%.^[38]

Recessive mutations in *HADH*

Mitochondrial fatty acid β -oxidation constitutes the essential physiological response to energy depletion caused by fasting, severe febrile illness or increased muscular activity. The process of β -oxidation results in production of acetyl-CoA by the sequential

oxidation and cleavage of straight-chain fatty acids. Importantly, hepatic β -oxidation provides the source of energy for extrahepatic tissues through ketone body formation upon fasting. *HADH* encodes for the enzyme L-3-hydroxyacyl-Coenzyme A dehydrogenase (HADH), (previously known as Short-chain L-3-Hydroxyacyl-CoA dehydrogenase SCHAD), which is an intra-mitochondrial enzyme that catalyses the penultimate step in the β -oxidation of fatty acids, the NAD^+ dependent dehydrogenation of 3-hydroxyacyl-CoA to the corresponding 3-ketoacyl-CoA. Human *HADH* encodes a 314-amino acid protein with 8 exons and spans approximately 49 kb.[96] It is composed of a 12-residue mitochondrial import signal peptide and a 302-residue mature HADH protein with a calculated molecular mass of 34.3kD.[97]

Loss-of-function mutations in the *HADH* gene are associated with CHI.[19-21] The clinical presentation of all patients reported is heterogeneous, with either mild late onset intermittent HH or severe neonatal hypoglycaemia. All reported cases have presented with increased 3-hydroxyglutarate in urine and hydroxybutyrylcarnitine in blood which may be diagnostically useful markers for HADH deficiency. In the first patient reported sequencing of the *HADH* genomic DNA from the fibroblasts showed a homozygous mutation (C773T) changing proline to leucine at amino acid 258.[19] Analysis of blood from the parents showed they were heterozygous for this mutation. Western blot studies showed undetectable levels of immunoreactive HADH protein in the patient's fibroblasts. Expression studies showed that the P258L enzyme had no catalytic activity. This patient presented with intermittent hypoglycaemia at 4 months of age.

A novel, homozygous deletion mutation (deletion of the six base pairs CAGGTC at the start of *HADH* exon 5) was found in the second patient who presented with severe neonatal hypoglycaemia.[21] The mutation affected RNA splicing and was predicted to

lead to a protein lacking 30 amino acids. The observations at the molecular level were confirmed by demonstrating greatly reduced HADH activity in the patients' fibroblasts and enhanced levels of 3-hydroxybutyryl-carnitine in their plasma. Urine metabolite analysis showed that HADH deficiency resulted in specific excretion of 3-hydroxyglutaric acid.[21] Finally the third patient reported to date was found to be homozygous for a splice site mutation (IVS6-2 a/g) in the *HADH* gene with western blotting with an anti-HADH antibody indicating a decrease in the amount of immunoreactive protein in fibroblasts from the patient consistent with the observed decrease in enzyme activity.[20]

The molecular mechanism of how loss of function in the *HADH* gene leads to unregulated insulin secretion is still unclear. Several recent studies in rodents have begun to give some insight into how *HADH* regulates insulin secretion and its interaction with other genes involved in β -cell development and function.[98-101] The normal β -cell phenotype is characterized by a high expression of *HADH* and a low expression of other β -oxidation enzymes. Down-regulation of *HADH* causes an elevated secretory activity suggesting that this enzyme protects against inappropriately high insulin levels and hypoglycemia.[98, 99] Hence HADH seems to be a negative regulator of insulin secretion in β -cells. Further studies will be required to fully understand the biochemical pathways by which defects in *HADH* lead to dysregulated insulin secretion.

Recent advances in the genetic aetiology of CHI

A further mechanism of hyperinsulinaemic hypoglycemia has been described whereby strenuous physical exercise causes an inappropriate burst of insulin release that can lead to hypoglycaemia. [102, 103] This work led to the identification of the molecular basis of exercise induced CHI, (due to mutations in *SLC16A1*). [42] Mutations in *HNF4A* have been recently reported to cause both transient and persistent hyperinsulinaemic

hypoglycaemia associated with macrosomia and a family history of and maturity onset diabetes of the young. [39, 41]

Dominant mutations in *SLC16A1* causing exercise induced CHI

In the glycolytic pathway glucose is metabolised to pyruvate which then enters in the mitochondria. Pyruvate can be converted into lactate or enters into the tricarboxylic acid (TCA) cycle, generating reducing equivalents. This leads to stimulation of the respiratory chain and ATP synthesis. The transport of monocarboxylates such as lactate and pyruvate is mediated by the SLC16A family of proton-linked membrane transport proteins known as monocarboxylate transporters (MCTs). Fourteen MCT-related genes have been identified in mammals and of these seven MCTs have been functionally characterized. Despite their sequence homology, only MCT1–4 have been demonstrated to be proton-dependent transporters of monocarboxylic acids.[104]

The *SLC16A1* gene encodes for MCT1 that mediates the movement of lactate and pyruvate across cell membranes. The *SLC16A1* gene maps to chromosome 1p13.2-p12, spans approximately 44 kb, and is organized as 5 exons intervened by 4 introns.[105,106] The first of these introns is located in the 5' UTR-encoding DNA, spans >26 kb, and thus accounts for approximately 60% of the entire transcription unit.[106] Analysis of a 1.5 kb fragment of the *MCT1* 5' flanking region, shows an absence of the classical TATA-Box motif. However, the region contains potential binding sites for a variety of transcription factors.[105]

Studies in whole rat and mouse islets have shown that pyruvate and lactate cannot mimic the effect of glucose on insulin secretion despite active metabolism.[107, 108]

This is postulated to be due to low expression of MCT in β -cells. However over

expression of LDH and MCT1 leads to pyruvate induced insulin secretion.[108] In exercise induced CHI there is increased expression of MCT1 transporter in β -cells due to dominant mutations in *SLC16A1*. [42] In these patients anaerobic physical exercise induces HH that is preceded by an inappropriate increase in the circulating insulin level.[102, 103] Affected patients become hypoglycemic within 30 min after a short period of anaerobic exercise. A pyruvate load test causes a brisk increase in the serum insulin concentration suggesting that pyruvate metabolism or transport is in some way is involved in signaling insulin secretion from β -cells in these patients.[109] A genome scan performed on two families with 10 affected patients first mapped the gene to chromosome 1.[42] Mutations in the promoter region of *SLC16A1* gene were confirmed in all patients. Studies on cultured fibroblasts from affected patients showed abnormally high *SLC16A1* transcript levels, although the MCT1 transport activity was unchanged in fibroblasts (possibly reflecting additional post-transcriptional control of MCT1 levels in extrapancreatic tissues).

Two of the *SLC16A1* mutations identified in separate pedigrees resulted in increased protein binding to the corresponding promoter elements and marked (3- or 10-fold) transcriptional stimulation of *SLC16A1* promoter-reporter constructs.[42] Some of the mutations were in the binding sites of several transcription factors (nuclear matrix protein 1, albumin negative factor (ANF) and AML-1a, simian- virus-40-protein-1 (Sp1), upstream stimulatory factor (USF), myeloid zinc finger 1 (MZF1) and GATA-1-binding site). These studies suggest that activating mutations in the promoter region of *SLC16A1* could induce increased expression of MCT1 in the β -cell (where this gene is not usually transcribed) allowing pyruvate uptake and pyruvate-stimulated insulin release despite ensuing hypoglycemia.[42]

Dominant heterozygous mutations in HNF4A

HNF4 α (hepatocyte nuclear factor 4alpha, HNF-4 α) is a transcription factor of the nuclear hormone receptor superfamily and is expressed in liver, kidney, gut, and pancreatic islets.[110] In combination with other hepatocyte nuclear factors, HNF4 α has been proposed to form a functional regulatory loop that regulates the development and function of the pancreas and the liver.[111, 112] In β -cells, HNF4 α has been shown to be the most widely acting transcription factor and regulates several key genes involved in glucose stimulated insulin secretion.[113, 114]

The *HNF4A* gene is located on human chromosome 20q13.1-13.2. The gene consists of at least 12 exons and spans 30 kb. The *HNF4A* gene has two promoters P1 and P2 with P2 being upstream to P1. The distant upstream P2 promoter represents the major transcription site in β -cells, and is also used in hepatic cells. Transfection assays with various deletions and mutants of the P2 promoter revealed functional binding sites for *HNF1A*, *HNF1B*, and *IPF1*. [115] The HNF4 α protein consists of an N-terminal ligand-independent transactivation domain (amino acids 1-24), a DNA binding domain containing two zinc fingers (amino acids 51-117), and a large hydrophobic portion (amino acids 163-368) composed of the dimerization, ligand binding, cofactor binding, and ligand-dependent transactivation domain.[116]

Heterozygote mutations in the human *HNF4A* gene classically lead to maturity onset diabetes of the young subtype 1 (MODY1), which is characterized by autosomal dominant inheritance and impaired glucose-stimulated insulin secretion from pancreatic β -cells.[117] These mutations in the *HNF4A* gene cause multiple defects in glucose stimulated insulin secretion and in expression of *HNF4A* dependent genes.[117, 118] Recently mutations in the *HNF4A* gene were reported to cause macrosomia and both

transient and persistent HH.[39-41] In one retrospective study the birth weight of the *HNF4A*-mutation carriers compared to non-mutation family members was increased by a median of 790 g.[39] Transient hypoglycaemia was reported in 8/54 infants with heterozygous *HNF4A* mutations and documented HH in three cases.[39]

In another prospective study three infants presented with macrosomia and severe HH with a positive family history of MODY.[41] All three patients required diazoxide therapy to maintain normoglycaemia. Sequencing of the *HNF4A* gene identified heterozygous mutations in all three families.[41] In family 1, a frameshift mutation L330fsdel17ins9 (c.987 1003del17ins9; p.Leu330fs) was present in the proband; a mutation affecting the conserved A nucleotide of the intron 2 branch site (c.264-21A>G) was identified in the proband of family 2; and finally a nonsense mutation, Y16X (c.48C>G, p.Tyr16X), was found in the proband of family 3.[41] Hence mutations in the *HNF4A* gene are a novel cause of both transient and persistent HH.

At present it is unclear how heterozygote mutations in *HNF4A* lead to hypoglycaemia. Using the conditional Cre-loxP-based inactivation system to delete *HNF4A* specifically in the pancreatic β - cell Gupta et al studied glucose homeostasis in the adult mice.[119] These mice were hyperinsulinaemic in fasted and fed state but also paradoxically had impaired glucose tolerance with inadequate insulin secretion after glucose stimulation. Cotransfection assays demonstrated that these mice had a 60% reduction in the expression of the Kir6.2 subunit of the potassium channel. However two further studies [39, 120] have reported no change in the expression of Kir6.2 in *HNF4A*- deficient mice suggesting that this loss of expression of Kir6.2 in the pancreatic with β -cell may not be the cause of the dysregulated insulin secretion. Hence, it is unclear how heterozygous mutations in the *HNF4A* gene cause HH in the newborn period followed by the opposite

phenotype of MODY-1 in young adulthood. Figure 4 summarises the genetic causes of CHI.

The genetic basis of focal CHI

CHI presents as **three (probably more, but these have not been fully defined yet)** different morphological forms: a diffuse form with functional abnormality of islets throughout the pancreas, **atypical form where the pathophysiology is unclear** and a focal form with focal islet cell adenomatous hyperplasia, which can be cured by partial pancreatectomy.[121] Focal CHI is characterized by nodular hyperplasia of islet-like cell clusters, including ductuloinsular complexes and hypertrophied insulin cells with giant nuclei.[122] The genetic aetiology of focal CHI is distinct from that of diffuse CHI. Focal adenomatous hyperplasia involves the specific loss of the maternal 11p15 region and a constitutional mutation of a paternally inherited allele of the genes *ABCC8/KCNJ11* encoding the K_{ATP} channel.[123-128] **The specific loss of the maternal 11p15 region within the focal region results in paternal isodisomy and a paternally inherited mutation in *ABCC8/KCNJ11*.** [124, 129] The reduction to homozygosity of a paternally inherited *ABCC8/KCNJ11* mutation within the focal lesion leads to uncontrolled secretion of insulin (figure 5).

Deletion mapping experiments have shown that the most commonly deleted region encompasses two regions of interest: the 11p15.5 region, subject to imprinting, and the 11p15.4 region containing the *ABCC8/ KCNJ11* genes, which are not imprinted.[123] The 11p15.5 chromosome region involved contains an imprinted domain, including several imprinted genes characterized by mono-allelic expression.[130-133] These include four maternally expressed genes (*H19* a candidate tumour suppressor gene,

P57KIP2 a negative regulator of cell proliferation, *KVLQT1* the gene coding for the potassium channel involved in the long QT syndrome, *HASH2* a transcription factor and one paternally expressed gene the insulin-like growth factor 2 (*IGF2*).[128, 132-136] The imbalance between imprinted genes (increased *IGF2* and diminished *H19* and *P57KIP2*) gives rise to the increase in proliferation of β -cells, a striking feature of focal adenomatous hyperplasia not observed in the diffuse form.[128] *H19* seems directly or indirectly to modulate cytoplasmic levels of the product of the *IGF2* allele and thus the *H19* gene seems to be an antagonist to *IGF2* in trans.[128] Figure 5 illustrates the genetic aetiology of a focal lesion.

The probability for this somatic chromosomal event occurring in a foetus carrying a heterozygous mutation of *ABCC8/KCNJ11* of paternal origin is about 1%.[128] Recently it was demonstrated that individual patients with focal CHI may have more than one focal pancreatic lesion due to separate somatic maternal deletion of the 11p15 region [137] and that some focal lesions have a duplication of the paternal allele on chromosome 11.[129]

Summary

CHI is a major cause of hypoglycaemia in the newborn and infancy period. So far mutations in seven different genes have been reported which lead to dysregulated insulin secretion. Recent advances have identified the molecular basis of exercise induced CHI (due to mutations in *SLC16A1*) and highlighted the intriguing link between transient (or persistent HH) and maturity onset diabetes of the young (due to mutations in *HNF4A*). Rapid genetic analysis for mutations in *ABCC8* and *KCNJ11* can be used as a powerful tool for differentiating between focal and diffuse disease in some patients and thus aid in patient management. Further genetic studies are required to understand the

molecular basis of CHI in patients where no mutations are found in the genes described so far.

Legends

Table 1: The genes implicated in congenital hyperinsulinism with the gene loci, proteins affected and patterns of inheritance (AD- autosomal dominant, AR- autosomal recessive).

Figure 1a: Schematic outline of the components of the β -cell K_{ATP} channel. The K_{ATP} channel is composed of two proteins: SUR1 which consists of 17 transmembrane domains with two intracellular nucleotide binding (NBF) motifs. Two N-linked glycosylation sites are present on amino acids 10 and 1049. Kir6.2 has 3 transmembrane segments. Common mutations in both of the proteins are highlighted.

Figure 1b: illustrating the hetero-octameric arrangement of the K_{ATP} channel

Figure 2: Schematic representation of the mutations in the GLUD1 gene known to cause CHI. Mutations are described to occur in three domains- the allosteric binding domain (exons 11 and 12), the catalytic domain (exons 6 and 7) and the antenna region (exon 10).

Figure 3: Schematic representation of the mutations in the GCK gene known to cause CHI

Figure 4: Summary of common mutations in the pancreatic β -cell leading to CHI; 1: The ATP gated potassium channel encoded by *ABCC8* and *KCNJ11*. 2: Glutamate dehydrogenase (GDH) encoded by *Glud1*. 3: Glucokinase (GCK), the initial enzyme in the glycolysis pathway. 4: L-3-hydroxyacyl-Coenzyme A dehydrogenase (HADH), the penultimate enzyme in the β -oxidation pathway encoded by *HADH*. 5: Mutations in

HNF4α cause multiple defects in glucose stimulated insulin secretion. 6: The monocarboxylate transporter MCT1 encoded by *SLC16A1*.

Figure 5: Genetic aetiology of a focal lesion. Fig 5a showing normal parental chromosomes 11 with the distal region of the short arm containing the *ABCC8* and *KCNJ11* channel genes, and imprinted genes (*H19* and *P57^{KIP2}* and *IGF2*), that influence cellular proliferation. Fig 5b explains the genetic basis of a focal lesion that results from paternal inheritance of a recessive *ABCC8* or *KCNJ11* mutation and the somatic loss of heterozygosity of the distal portion of the short arm of chromosome 11.

References

1. Stanley CA. Hyperinsulinism in infants and children. *Pediatr Clin North Am*. 1997;**44**(2): 363-74.
2. Hussain K, Blankenstein O, De Lonlay P, Christesen HT. Hyperinsulinaemic hypoglycaemia: biochemical basis and the importance of maintaining normoglycaemia during management. *Arch Dis Child* 2007;**92**(7):568-70.
3. Bruninig GJ. Recent advances in hyperinsulinism and the pathogenesis of diabetes mellitus. *Curr Opin Pediatr* 1990;**2**:758-765
4. Fournet JC and Junien C. The genetics of neonatal hyperinsulinism. *Horm Res* 2003;**59**:30–34,.
5. Glaser B, Thornton PS, Otonkoski T, and Junien C. The genetics of neonatal hyperinsulinism. *Arch Dis Child* 2000;**82**:79–86.
6. de Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fékété C, Saudubray JM, Robert JJ. Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. *Eur J Pediatr* 2002;**161**(1):37-48.
7. Meissner T, Mayatepek E. Clinical and genetic heterogeneity in congenital hyperinsulinism. *Eur J Pediatr* 2002;**161**(1):6-20.
8. Sempoux C, Guiot Y, Lefevre A, Nihoul-Fekete C, Jaubert F, Saudubray JM, Rahier J. Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome and keys for differential diagnosis. *J Clin Endocrinol Metab* 1998;**83**:1455-1461.
9. Nestorowicz A, Glaser B, Wilson BA, Shyng SL, Nichols CG, Stanley CA, Thornton PS, Permutt MA. Genetic heterogeneity in familial hyperinsulinism. *Hum Mol Genet* 1998;**7**(7):1119-28.

10. Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. *Hum Mol Genet* 1996;**5(11)**:1809-12.
11. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. *Science* 1995;**21**;268(5209):426-9.
12. Nestorowicz A, Inagaki N, Gono T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA, Thornton PS, Seino S, Permutt MA. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. *Diabetes* 1997;**46(11)**:1743-8.
13. Dunne MJ, Kane C, Shepherd RM, Sanchez JA, James RF, Johnson PR, Aynsley-Green A, Lu S, Clement JP IV, Lindley KJ, Seino S, and Aguilar-Bryan L. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. *N Engl J Med* 1997;**336**:703–706
14. Otonkoski T, Ammala C, Huopio H, Cote GJ, Chapman J, Cosgrove K, Ashfield R, Huang E, Komulainen J, Ashcroft FM, Dunne MJ, Kere J, Thomas PM. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. *Diabetes* 1999;**48(2)**:408-15
15. Tanizawa Y, Matsuda K, Matsuo M, Ohta Y, Ochi N, Adachi M, Koga M, Mizuno S, Kajita M, Tanaka Y, Tachibana K, Inoue H, Furukawa S, Amachi T, Ueda K, and Oka Y. Genetic analysis of Japanese patients with persistent hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2 mutation impairs cooperative binding of adenine nucleotides to sulfonylurea receptor 1. *Diabetes* 2000;**49**:114–120
16. Marthinet E, Bloc A, Oka Y, Tanizawa Y, Wehrle-Haller B, Bancila V, Dubuis JM, Philippe J, Schwitzgebel VM. Severe congenital hyperinsulinism caused by a mutation in

the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function. *J Clin Endocrinol Metab* 2005;**90(9)**:5401-6

17. Tornovsky S, Crane A, Cosgrove KE, Hussain K, Lavie J, Heyman M, Nesher Y, Kuchinski N, Ben-Shushan E, Shatz O, Nahari E, Potikha T, Zangen D, Tenenbaum-Rakover Y, de Vries L, Argente J, Gracia R, Landau H, Eliakim A, Lindley K, Dunne MJ, Aguilar-Bryan L, Glaser B. Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity. *J Clin Endocrinol Metab* 2004;**89(12)**:6224-34

18. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. *Nature* 1984;**312(5993)**:446-448

19. Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, van den Berg IE. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. *J Clin Invest* 2001;**108(3)**:457-65

20. Hussain K, Clayton PT, Krywawych S, Chatziandreou I, Mills P, Ginbey DW, Geboers AJ, Berger R, van den Berg IE, Eaton S. Hyperinsulinism of infancy associated with a novel splice site mutation in the SCHAD gene. *J Pediatr* 2005;**146(5)**:706-8.

21. Molven A, Matre GE, Duran M, Wanders RJ, Rishaug U, Njolstad PR, Jellum E, Sovik O. Familial hyperinsulinaemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. *Diabetes* 2004;**53(1)**:221-7.

22. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, Vauhkonen I, Kere J, Laakso M, Ashcroft F, Otonkoski T. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. *J Clin Invest* 2000;**106(7)**:897-906.

23. Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, Crane A, Aguilar-Bryan L, Stanley CA. Clinical and molecular characterization of a dominant form of

- congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. *Diabetes* 2003;**52(9)**:2403-10.
24. Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, Thornton P, Ganguly A, Shyng SL, Stanley CA. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. *J Clin Invest* 2008;**118(8)**:2877-86.
25. Lin YW, Macmullen C, Ganguly A, Stanley CA, Shyng SL. A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels. *J Biol Chem* 2006;**281(5)**:3006-12
26. Stanley CA, Lieu YK, Hsu BYL, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. *N Engl J Med* 1998;**338**:1352–1357
27. Stanley CA, Fang J, Kutyna K, Hsu BY, Ming JE, Glaser B, Poncz M. Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. *Diabetes* 2000;**49**:667–673
28. Yorifuji T, Muroi J, Uematsu A, Hiramatsu H, Momoi T. Hyperinsulinism hyperammonemia syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics. *Hum Genet* 1999;**104**:476–479
29. Miki Y, Taki T, Ohura T, Kato H, Yanagisawa M, Hayashi Y Novel missense mutations in the glutamate dehydrogenase gene in the congenital hyperinsulinism hyperammonemia syndrome. *J Pediatr* 2000;**136**:69–72
30. Santer R, Kinner M, Passarge M, Superti-Furga A, Mayatepek E, Meissner T, Schneppenheim R, Schaub J. Novel missense mutations outside the allosteric domain of

- glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism-hyperammonemia syndrome. *Hum Genet* 2001;**108(1)**:66-71.
31. Fujioka H, Okano Y, Inada H, Asada M, Kawamura T, Hase Y, Yamano T. Molecular characterisation of glutamate dehydrogenase gene defects in Japanese patients with congenital hyperinsulinism/hyperammonaemia. *Eur J Hum Genet* 2001;**9**:931–937
32. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC. Familial hyperinsulinism caused by an activating glucokinase mutation. *N Engl J Med* 1998;**338(4)**:226-30.
33. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. *Diabetes* 2002;**51(4)**:1240-6.
34. Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, Midgley P, Shiota C, Buettger C, Magnuson MA, Matschinsky FM, Hattersley AT. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. *Diabetes* 2003;**52(9)**:2433-40.
35. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, Lopez-Enriquez S, Garcia-Gimeno MA, Sanz P, Soriguer FC, Laakso M. Severe Persistent Hyperinsulinemic Hypoglycemia due to a De Novo Glucokinase Mutation. *Diabetes* 2004;**53(8)**:2164-8.
36. Dullaart RP, Hoogenberg K, Rouwe CW & Stulp BK. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. *Journal of Internal Medicine* 2004;**255**:143–145.
37. Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, Fenneberg A, Debatin KM, Klein R, Ellard S, Clark A, Gloyn AL. Heterogeneity in

disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. *Diabet Med* 2007;**24(12)**:1393-9.

38. Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, Ellard S, Njølstad PR, Alm J, Brock Jacobsen B, Hussain K, Gloyn AL. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. *Eur J Endocrinol* 2008;**159(1)**:27-34.

39. Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. *PLoS Med* 2007;**4(4)**:e118.

40. Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4alpha (HNF4A). *Diabetologia* 2007;**50(12)**:2600-1.

41. Kapoor R, Locke J, Colclough K, Wales J, Conn J, Ellard S, Hussain K. Persistent Hyperinsulinaemic Hypoglycaemia and Maturity Onset Diabetes of the Young (MODY) due to Heterozygous HNF4A Mutations. *Diabetes* 2008;**57(6)**:1659-63.

42. Otonkoski T, Jiao H, Kaminen-Ahola N, Tapia-Paez I, Ullah MS, Parton LE, Schuit F, Quintens R, Sipila I, Mayatepek E, Meissner T, Halestrap AP, Rutter GA, Kere J. Physical exercise-induced hypoglycemia caused by failed silencing of monocarboxylate transporter 1 in pancreatic Beta cells. *Am J Hum Genet* 2007;**81(3)**:467-74.

43. Fournet JC, Junien C. Genetics of congenital hyperinsulinism. *Endocr Pathol* 2004;**15(3)**:233-40.

44. Someya T, Miki T, Sugihara S, Minagawa M, Yasuda T, Kohno Y, and Seino S. Characterization of genes encoding the pancreatic β -cell ATP-sensitive K^+ channel in persistent hyperinsulinemic hypoglycemia of infancy in Japanese patients. *Endocr J* 2000;**47**:715–722.

45. Rahier J, Guiot Y, Sempoux C. Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. *Arch Dis Child Fetal Neonatal Ed* 2002;**82(2)** F108-12.
46. Hussain K, Flanagan SE, Smith VV, Ashworth M, Day M, Pierro A, Ellard S. An *ABCC8* gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. *Diabetes*. 2008;**57(1)**:259-63.
47. Kapoor R, James C, Hussain K. Recent advances in the diagnosis and management of hyperinsulinaemic hypoglycaemia. *Nat Clin Pract Endocrinol Metab* (in press)
48. Peranteau WH, Ganguly A, Steinmuller L, Thornton P, Johnson MP, Howell LJ, Stanley CA, Adzick NS. Prenatal diagnosis and postnatal management of diffuse congenital hyperinsulinism: a case report. *Fetal Diagn Ther* 2006;**21(6)**:515-8.
49. Seino S, & Miki T. Physiological and pathophysiological roles of ATP-sensitive K⁺ channels. *Prog. Biophys. Mol. Biol* 2003;**81**,133–176.
50. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. *J Clin Invest* 2005;**115(8)**:2047-58.
51. Ashcroft FM. Adenosine 5'-triphosphate-sensitive potassium channels. *Annu. Rev. Neurosci.* 1988;**11**,97-118.
52. Inagaki N, Gonoi T, Clement JP 4th, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J. Reconstitution of KATP: An inward rectifier subunit plus the sulphonylurea receptor. *Science* 1995;**270**:1166-1170.
53. Tucker SJ, Gribble FM, Proks P, Trapp S, Ryder TJ, Haug T, Reimann F, Ashcroft FM. Molecular determinants of K-ATP channel inhibition by ATP. *EMBO J* 1998;**17**,3290–3296.
54. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. *Endocr Rev* 1999;**20**:101-135.

55. Heron L, Virsolvy A, Peyrollier K, Gribble F M, Le Cam A, Ashcroft FM, and Bataille D. Human α -endosulfine, a possible regulator of sulfonylurea-sensitive K_{ATP} channel: Molecular cloning, expression and biological properties. *Proc Natl Acad Sci* 1998;95;14:8387-91
56. Conti LR, Radeke CM, Shyng SL, Vandenberg CA. Transmembrane topology of the sulfonylurea receptor SUR1. *J Biol Chem* 2001;276:41270-41278.
57. Ueda K, Komine J, Matsuo M, Seino S, Amachi T. Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. *Proc Natl Acad Sci U S A* 1999;96(4):1268-72.
58. Matsuo M, Kimura Y, Ueda K. KATP channel interaction with adenine nucleotides. *J Mol Cell Cardiol* 2005;38(6):907-16.
59. Zerangue N, Schwappach B, Jan YN, Jan LY. A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels. *Neuron* 1999;22(3):537-48.
60. Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM. Truncation of Kir6.2 produces ATP-sensitive K^+ channels in the absence of the sulphonylurea receptor. *Nature* 1997;387 (6629),179–183.
61. Sharma N, Crane A, Clement, JPt. Gonzalez G, Babenko AP, Bryan J, Aguilar-Bryan L. The C terminus of SUR1 is required for trafficking of KATP channels. *J. Biol. Chem* 1999;274 (29),20628–20632.
62. Babenko AP, Aguilar-Bryan L, Bryan J. A view of sur/KIR6.X, KATP channels. *Annu Rev Physiol* 1998;60:667-87.
63. Clement JP 4th, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J. Association and stoichiometry of K(ATP) channel subunits. *Neuron* 1997;18: 827-38.

64. Aguilar-Bryan L, Clement JP IV, Gonzalez G, Kunjilwar K, Babenko A, and Bryan J. Toward understanding the assembly and structure of K_{ATP} channels. *Physiol Rev* 1998;**78**:227–245.
65. Inagaki N, Gonoi T, Clement JP, Wang CZ, Aguilar-Bryan L, Bryan J, Seino S. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K^+ channels. *Neuron* 1996;**16**(5):1011-7.
66. Aguilar-Bryan L, Nichols GC, Wechsler WS, Clement JP IV, Boyd AE III, Gonzalez G, Herrers-Sosa E, Nguy K, Bryan J, Nelson DA. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. *Science* 1995 ;**268**:423–426.
67. Bitner-Glindzicz M, Lindley KJ, Rutland P, Blaydon D, Smith VV, Milla PJ, Hussain K, Furth-Lavi J, Cosgrove KE, Shepherd RM, Barnes PD, O'Brien RE, Farndon PA, Sowden J, Liu XZ, Scanlon MJ, Malcolm S, Dunne MJ, Aynsley-Green A, Glaser B. A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher Type 1C gene. *Nat Gene* 2000;**26**:56-60.
68. Fernández-Marmiesse A, Salas A, Vega A, Fernández-Lorenzo JR, Barreiro J, Carracedo A. Mutation spectra of ABCC8 gene in Spanish patients with Hyperinsulinism of Infancy (HI). *Hum Mutat* 2006;**27**(2):214.
69. Flanagan SE, Clauin S, Bellanné-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, Ellard S. Update of mutations in the genes encoding the pancreatic beta-cell $K(ATP)$ channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. *Hum Mutat*. Published Online First 2 Sep 2008.
70. Dekel B, Lubin D, Modan-Moses D, Quint J, Glaser B, Meyerovitch J. Compound heterozygosity for the common sulfonylurea receptor mutations can cause mild diazoxide-sensitive hyperinsulinism. *Clin Pediatr (Phila)* 2002;**41**(3):183-6.

71. Muzyamba M, Farzaneh T, Behe P, Thomas A, Christesen HB, Brusgaard K, Hussain K, Tinker A. Complex ABCC8 DNA variations in congenital hyperinsulinism: lessons from functional studies. *Clin Endocrinol (Oxf)* 2007;**67(1)**:115-24.
72. Crane A, Aguilar-Bryan L. Assembly, maturation, and turnover of K(ATP) channel subunits. *J Biol Chem* 2004;**279**:9080–9090.
73. Cartier EA, Conti LR, Vandenberg CA, and Shyng SL. Defective trafficking and function of K_{ATP} channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. *Proc Natl Acad Sci USA* 2001;**98**:2882–2887.
74. Partridge CJ, Beech DJ, and Sivaprasadarao A. Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism. *J Biol Chem* 2001;**276**:35947–35952.
75. Shyng SL, Ferrigni T, Shepard JB, Nestorowicz A, Glaser B, Permutt MA, and Nichols CG. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. *Diabetes* 1998;**47**:1145–1151.
76. Taschenberger G, Mougey A, Shen S, Lester LB, LaFranchi S, Shyng SL. Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. *J Biol Chem* 2002;**277(19)**:7139-46.
77. Matsuo M, Trapp S, Tanizawa Y, Kioka N, Amachi T, Oka Y, Ashcroft FM, and Ueda K. Functional analysis of a mutant sulfonylurea receptor, SUR1–R1420C, that is responsible for persistent hyperinsulinemic hypoglycemia of infancy. *J Biol Chem* 2000;**275**:41184–41191.

78. Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement JP 4th, Gonzalez G, Aguilar-Bryan L, Permutt MA, Bryan J. Adenosine diphosphate as an intracellular regulator of insulin secretion. *Science* 1996;**272(5269)**:1785-7.
79. Branstrom R, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O. Long chain coenzyme A esters activate the pore-forming subunit (Kir6. 2) of the ATP-regulated potassium channel. *J Biol Chem* 1998;**273(47)**:31395-400.
80. Deloukas P, Dauwerse JG, Moschonas NK, van Ommen GJ, van Loon AP. Three human glutamate dehydrogenase genes (GLUD1, GLUDP2, and GLUDP3) are located on chromosome 10q, but are not closely physically linked. *Genomics* 1993;**17**:676–681.
81. Hudson RC, Daniel RM. L-glutamate dehydrogenases: distribution, properties and mechanism. *Comp Biochem Physiol B* 1993;**106(4)**:767-92.
82. Kelly A, Li C, Gao Z, Stanley CA, Matschinsky FM. Glutaminolysis and Insulin Secretion: From Bedside to Bench and Back. *Diabetes* 2002;**51**:S421-6.
83. Fahien LA, MacDonald MJ, Kmietek EH, Mertz RJ, Fahien CM: Regulation of insulin release by factors that also modify glutamate dehydrogenase. *J Biol Chem* 1980;**263**:13610–13614.
84. Weinzimer SA, Stanley CA, Berry GT, Yudkoff M, Tuchman M, Thornton PS. A syndrome of congenital hyperinsulinism and hyperammonemia. *J Pediatr* 1997;**130**:661-664.
85. Zammarchi E, Filippi L, Novembre E, Donati MA. Biochemical evaluation of a patient with a familial form of leucine-sensitive hypoglycemia and concomitant hyperammonemia. *Metabolism* 1996;**45(8)**:957-60.
86. Stanley CA. Hyperinsulinism/hyperammonemia syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism. *Mol Genet Metab* 2004;**81**:S45-51.
87. Raizen DM, Brooks-Kayal A, Steinkrauss L, Tennekoon GI, Stanley CA, Kelly A.

Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations. *J Pediatr* 2005;**146(3)**:388-94.

88. MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, Ganguly A, Smith TJ, Stanley CA; Hyperinsulinism/hyperammonemia Contributing Investigators. Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. *J Clin Endocrinol Metab* 2001;**86(4)**:1782-7.

89. Iynedjian PB, Möbius G, Seitz HJ, Wollheim CB, Renold AE. Tissue-specific expression of glucokinase: identification of the gene product in liver and pancreatic islets. *Proc Natl Acad Sci U S A* 1986;**83(7)**:1998-2001.

90. Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. *Diabetes* 2002;**51**:S394-404.

91. Zelent D, Najafi H, Odili S, Buettger C, Weik-Collins H, Li C, Doliba N, Grimsby J, Matschinsky FM. Glucokinase and glucose homeostasis: proven concepts and new ideas. *Biochem Soc Trans* 2005;**33(Pt 1)**:306-10.

92. Ralph EC, Thomson J, Almaden J, Sun S. Glucose modulation of glucokinase activation by small molecules. *Biochemistry* 2008;**47(17)**:5028-36.

93. Heredia VV, Carlson TJ, Garcia E, Sun S. Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations. *J Biol Chem* 2006;**281(52)**:40201-7.

94. Van de Bunt M, Edghill ML, Hussain K, Ellard S, Gloyn A. Gene duplications resulting in over expression of glucokinase are not a common cause of hypoglycaemia of infancy in humans. *Mol Genet Metab* 2008;**94(2)**:268-9.

95. Christesen HB, Brusgaard K, Beck Nielsen H, Brock Jacobsen B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase

- mutation: Hypoglycaemia unawareness and attacks. *Clin Endocrinol (Oxf)* 2008;
68(6):1011.
96. Vredendaal PJ, van den Berg IE, Malingré HE, Stroobants AK, Olde Weghuis DE, Berger Human short-chain L-3-hydroxyacyl-CoA dehydrogenase: cloning and characterization of the coding sequence. *Biochem Biophys Res Commun* 1996;**223(3)**:718-23.
97. Vredendaal PJ, van den Berg IE, Stroobants AK, van der A DL, Malingré HE, Berger R. Structural organization of the human short-chain L-3-hydroxyacyl-CoA dehydrogenase gene. *Mamm Genome* 1998;**9(9)**:763-8.
98. Hardy OT, Hohmeier HE, Becker TC, Manduchi E, Doliba NM, Gupta RK, White P, Stoeckert CJ Jr, Matschinsky FM, Newgard CB, Kaestner KH. Functional genomics of the beta-cell: short-chain 3-hydroxyacyl-coenzyme A dehydrogenase regulates insulin secretion independent of K⁺ currents. *Mol Endocrinol* 2007;**21(3)**:765-73.
99. Martens GA, Vervoort A, Van de Castele M, Stangé G, Hellemans K, Van Thi HV, Schuit F, Pipeleers D. Specificity in beta cell expression of L-3-hydroxyacyl-CoA dehydrogenase, short chain, and potential role in down-regulating insulin release. *J Biol Chem* 2007;**282(29)**:21134-44. .
100. Lantz KA, Vatamaniuk MZ, Brestelli JE, Friedman JR, Matschinsky FM, Kaestner KH. Foxa2 regulates multiple pathways of insulin secretion. *J Clin Invest* 2004;**14(4)**:512-20.
101. Sund NJ, Vatamaniuk MZ, Casey M, Ang SL, Magnuson MA, Stoffers DA, Matschinsky FM, Kaestner KH. Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. *Genes Dev* 2001;**15(13)**:1706-15.
102. Meissner T, Otonkoski T, Feneberg R, Beinbrech B, Apostolidou S, Sipilä I, Schaefer F, Mayatepek E. Exercise induced hypoglycaemic hyperinsulinism. *Arch Dis Child* 2001;**84(3)**:254-7.

103. Meissner T, Friedmann B, Okun JG, Schwab MA, Otonkoski T, Bauer T, Bärtsch P, Mayatepek E. Massive insulin secretion in response to anaerobic exercise in exercise-induced hyperinsulinism. *Horm Metab Res* 2005;**37(11)**:690-4.
104. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. *Biochem. J* 1999;**343**(Pt 2):281–299.
105. Cuff MA, Shirazi-Beechey SP. The human monocarboxylate transporter, MCT1: genomic organization and promoter analysis. *Biochem Biophys Res Commun* 2002;**292**:1048–1056.
106. Garcia CK, Li X, Luna J, Francke U. cDNA cloning of the human monocarboxylate transporter 1 and chromosomal localization of the SLC16A1 locus to 1p13.2-p12. *Genomics* 1994;**23(2)**:500-3.
107. Zhao C, Rutter GA. Overexpression of lactate dehydrogenase A attenuates glucose-induced insulin secretion in stable MIN-6 beta-cell lines. *FEBS Lett* 1998;**430**:213–216.
108. Ishihara H, Wang H, Drewes LR, Wollheim CB. Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in beta cells. *J Clin Invest* 1999;**104**:1621–1629.
109. Otonkoski T, Kaminen N, Ustinov J, Lapatto R, Meissner T, Mayatepek E, Kere J, Sipilä I. Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. *Diabetes* 2003;**52(1)**:199-204.
111. Sladek FM, Zhong WM, Lai E, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. *Genes Dev* 1990;**4(12B)**:2353-65.
112. Boj SF, Parrizas M, Maestro MA, Ferrer J. A transcription factor regulatory circuit in differentiated pancreatic cells. *Proc Natl Acad Sci U S A* 2001;**98(25)**:14481-6.

113. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA. Control of pancreas and liver gene expression by HNF transcription factors. *Science* 2004;**303(5662)**:1378-81.
114. Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB. Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. *J Biol Chem* 2000;**275(46)**:35953-9.
115. Hadzopoulou-Cladaras M, Kistanova E, Evagelopoulou C, Zeng S, Cladaras C, and Ladias JAA. Functional Domains of the Nuclear Receptor Hepatocyte Nuclear Factor 4. *J. Biol. Chem* 1997;**272**: 539-550.
116. Thomas H, Jaschowitz K, Bulman M, Frayling TM, Mitchell SM, Roosen S, Lingott-Frieg A, Tack CJ, Ellard S, Ryffel GU, Hattersley AT. A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young. *Hum Mol Genet* 2001;**10(19)**:2089-97.
117. Yamagata K, Furuta H, Oda N, Kaisaki P, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, and Bell GI. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). *Nature* 1996;**384(6608)**:458-60.
118. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. *Proc Natl Acad Sci U S A* 1997;**94(24)**:13209-14.
119. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, Kaestner KH. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. *J Clin Invest* 2005;**115(4)**:1006-15.

120. Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, Magnuson MA, Kasai H, Miyagawa J, Gonzalez FJ, Shimomura I. Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. *J Biol Chem* 2006;**281(8)**:5246-57.
121. Rahier J, Guiot Y, Sempoux C. Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. *Arch Dis Child Fetal Neonatal Ed* 2000;**82(2)**:F108-12.
122. Goossens A, Gepts W, Saudubray JM, Bonnefont JP, Nihoul-Fekete , Heitz PU, Klöppel G. Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. *Am J Surg Pathol* 1989;**13(9)**:766-75.
123. Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. *J Clin Invest* 1998;**102(7)**:1286-91.
124. de Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C. Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. *J Clin Invest* 1997;**100(4)**:802-7.
125. Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, Barton DE, Thornton PS. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. *Diabetes* 1999;**48(8)**:1652-7.

126. Ryan F, Devaney D, Joyce C, Nestorowicz A, Permutt MA, Glaser B, Barton DE, Thornton PS. Hyperinsulinism: molecular aetiology of focal disease. *Arch Dis Child* 1998;**79(5)**:445-7.
127. Fournet JC, Mayaud C, de Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C. Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. *Am J Pathol* 2001;**158(6)**:2177-84.
128. Fournet JC, Mayaud C, de Lonlay P, Verkarre V, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C. Loss of imprinted genes and paternal SUR1 mutations lead to focal form of congenital hyperinsulinism. *Horm Res* 2000;**53**:2-6.
129. Damaj L, le Lorch M, Verkarre V, Werl C, Hubert L, Nihoul-Fékété C, Aigrain Y, de Keyzer Y, Romana SP, Bellanne-Chantelot C, de Lonlay P, Jaubert F. Chromosome 11p15 Paternal Isodisomy in Focal Forms of Neonatal Hyperinsulinism *J Clin Endocrinol Metab.* 2008;**93**:12:4941-47.
130. Giannoukakis N, Deal C, Paquette J, Goodyer C, Polychronakos C: Parental genomic imprinting of the human IGF2 gene. *Nat Genet* 1993;**4**:98–101.
131. Lee MP, Hu R-J, Johnson LA, Feinberg AP: Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. *Nat Genet* 1997;**15**:181–185.
132. Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A, Harper J, Elledge S: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. *Genes Dev* 1995;**9**:650–662.
133. Zhang Y, Tycko B: Monoallelic expression of the human H19 gene. *Nat Genet* 1992;**1**:40–44.


134. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumour-suppressor activity of H19 RNA. *Nature* 1993;**365**:764–767.
135. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi S, Fukushima Y, Iida K, Yutani C, Takahashi S, Chiba Y, Ohishi S, Mukai T: Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. *Hum Mol Genet* 1996;**5**:783–788.
136. Guillemot F, Caspary T, Tilghman SM, Copeland NG, Gilbert DJ, Jenkins NA, Anderson DJ, Joyner AL, Rossant J, Nagy A: Genomic imprinting of Mash2, a mouse gene required for trophoblast development. *Nat Genet* 1995;**9**:235–242.
137. Giurgea I, Sempoux C, Bellanné-Chantelot C, Ribeiro M, Hubert L, Boddaert N, Saudubray JM, Robert JJ, Brunelle F, Rahier J, Jaubert F, Nihoul-Fékété C, de Lonlay P. The Knudson's two-hit model and timing of somatic mutation may account for the phenotypic diversity of focal congenital hyperinsulinism. *J Clin Endocrinol Metab* 2006;**91(10)**:4118-23.
138. Chik KK, Chan CW, Lam CW, Ng KL. Hyperinsulinism and hyperammonaemia syndrome due to a novel missense mutation in the allosteric domain of the Glutamate dehydrogenase 1 gene. *J Paediatr Child Health* 2008;**44(9)**:517-9.

Table 1:

Gene (locus)	#OMIM	Protein	Mechanism	Inheritance
ABCC8 (11p15.1)	600509	Sulphonylurea receptor1 (SUR1)	Defects in K _{ATP} biogenesis and turnover, trafficking and nucleotide regulation	AR/ AD
KCNJ11 (11p15.1)	600937	Inward rectifying potassium channel (Kir6.2)	Defects in K _{ATP} biogenesis and turnover, trafficking and nucleotide regulation	AR/ AD
GLUD1 (10q23.3)	138130	Glutamate dehydrogenase (GDH)	Loss of inhibition of GDH by GTP and increased basal GDH activity	AD
GCK (7p15-13)	138079	Glucokinase	Increased affinity of GCK for glucose	AD
HADH (4q22-26)	601609	3-hydroxyacyl-CoA dehydrogenase	Unknown	AR
SLC16A1 (1p13.2-p12)	600682	Monocarboxylate transporter 1 (MCT1)	Increased expression of MCT1	AD
HNF4A (20q12-13.1)	600281	Hepatocyte nuclear factor 4 alpha	Unknown	AD

Figure 1a and 1b

1a



1b




Figure 2




Figure 3




Figure 4




Figure 5a and 5b

